BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW)
Post# of 37042
(Total Views: 96)
Posted On: 02/07/2024 3:40:54 PM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
https://finance.yahoo.com/news/briacell-annou...00153.html
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment
https://finance.yahoo.com/news/briacell-annou...00153.html
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell’s pivotal Phase 3 study
Disease control rate of 50% in evaluable patients treated with the Phase 3 formulation who failed prior antibody-drug conjugate (ADC) therapy
Notable responder had failed 4 prior therapies including ADC therapy with metastatic liver tumor “no longer observed” following BriaCell treatment
(0)
(0)Scroll down for more posts ▼